| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Dong-Wei Shao, Li-Jie Zhao, Jin-Feng Su. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM). European journal of medicinal chemistry. vol 272. 2024-05-05. PMID:38704940. |
the inhibition of dpp-4 has become a promising treatment approach for t2dm because it can increase levels of active glucagon-like peptide-1 (glp-1), leading to improved insulin secretion in response to glucose and reduced release of glucagon. |
2024-05-05 |
2024-05-08 |
Not clear |
| Celine B E Busch, Suzanne Meiring, Annieke C G van Baar, Frits Holleman, Max Nieuwdorp, Jacques J G H M Bergma. Re-Cellularization via Electroporation Therapy of the duodenum combined with GPL-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes; 12 months results of a first-in-human study. Gastrointestinal endoscopy. 2024-05-01. PMID:38692517. |
in this study, we aimed to eliminate exogenous insulin treatment in t2d patients through a single recet procedure combined with a glp-1 receptor agonist (glp-1ra). |
2024-05-01 |
2024-05-04 |
Not clear |
| Riccardo Candido, Antonio Nicolucci, Monica Larosa, Maria Chiara Rossi, Raffaele Napol. Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2024-05-01. PMID:38693036. |
treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: comparative effectiveness analyses between free vs. fixed combination of glp-1 ra and basal insulin. |
2024-05-01 |
2024-05-04 |
Not clear |
| Riccardo Candido, Antonio Nicolucci, Monica Larosa, Maria Chiara Rossi, Raffaele Napol. Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2024-05-01. PMID:38693036. |
add-on of basal insulin (bi) to intensify the ongoing therapy with glucagon-like peptide 1 receptor agonist (glp-1 ra) is recommended, but it is unclear if free or fixed combination of bi and glp-1 ra produce similar outcomes. |
2024-05-01 |
2024-05-04 |
Not clear |
| João Carlos Locatelli, Juliene Gonçalves Costa, Andrew Haynes, Louise H Naylor, P Gerry Fegan, Bu B Yeap, Daniel J Gree. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes care. 2024-04-30. PMID:38687506. |
liraglutide and semaglutide (glp-1ra), tirzepatide (glp-1 and gip receptor dual agonist), and retatrutide (glp-1, gip, and glucagon receptor triple agonist) are peptides with incretin agonist activity that induce ∼15-24% weight loss in adults with overweight and obesity, alongside beneficial impacts on blood pressure, cholesterol, blood glucose, and insulin. |
2024-04-30 |
2024-05-03 |
Not clear |
| Abdulrahman Alhajahjeh, Raad Al-Faouri, Hisham F Bahmad, Taima' Bader, Ryan W Dobbs, Ahmed A Abdulelah, Wassim Abou-Kheir, Elai Davicioni, David I Lee, Mohammed Shahai. From Diabetes to Oncology: Glucagon-like Peptide-1 (GLP-1) Receptor Agonist's Dual Role in Prostate Cancer. Cancers. vol 16. issue 8. 2024-04-27. PMID:38672620. |
glucagon-like peptide-1 (glp-1), an incretin hormone renowned for its role in post-meal blood sugar regulation and glucose-dependent insulin secretion, has gained attention as a novel treatment for diabetes through glp-1 receptor agonists (glp-1-ra). |
2024-04-27 |
2024-04-29 |
Not clear |
| Jorge E Jalil, Luigi Gabrielli, María Paz Ocaranza, Paul MacNab, Rodrigo Fernández, Bruno Grassi, Paulina Jofré, Hugo Verdejo, Monica Acevedo, Samuel Cordova, Luis Sanhueza, Douglas Grei. New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review. International journal of molecular sciences. vol 25. issue 8. 2024-04-27. PMID:38673991. |
glp-1 reduces blood glucose levels by stimulating insulin synthesis, suppressing islet α-cell function, and promoting the proliferation and differentiation of β-cells. |
2024-04-27 |
2024-04-29 |
Not clear |
| Soumia Majait, Emma C E Meessen, Mark Davids, Youssef Chahid, Steven W Olde Damink, Frank G Schaap, Ellis Marleen Kemper, Max Nieuwdorp, Maarten R Soeter. Age-Dependent Differences in Postprandial Bile-Acid Metabolism and the Role of the Gut Microbiome. Microorganisms. vol 12. issue 4. 2024-04-27. PMID:38674708. |
postprandial bile-acid levels, insulin, glucose, glp-1, c4, fgf19 and lipids were measured. |
2024-04-27 |
2024-04-29 |
Not clear |
| Maria-Christina Kanata, Amalia E Yanni, Chrysi Koliaki, Irene Pateras, Ioanna A Anastasiou, Alexander Kokkinos, Vaios T Karathano. Effects of Wheat Biscuits Enriched with Plant Proteins Incorporated into an Energy-Restricted Dietary Plan on Postprandial Metabolic Responses of Women with Overweight/Obesity. Nutrients. vol 16. issue 8. 2024-04-27. PMID:38674919. |
the responses of glucose, insulin, ghrelin, glp-1, and glicentin were evaluated over 180 min. |
2024-04-27 |
2024-04-29 |
human |
| Jenpei Lee, Yingxiao Li, Juei-Tang Cheng, I-Min Liu, Kai-Chun Chen. Development of Syringaldehyde as an Agonist of the GLP-1 Receptor to Alleviate Diabetic Disorders in Animal Models. Pharmaceuticals (Basel, Switzerland). vol 17. issue 4. 2024-04-27. PMID:38675498. |
in addition, sa stimulated insulin production in min-6 cells by activating glp-1 receptors. |
2024-04-27 |
2024-04-29 |
rat |
| Rayaz A Malik, Chii-Min Hwu, Anwar A Jammah, Juan M Arteaga-Díaz, Khier Djaballah, Valerie Pilorget, Agustina Alvarez, Carine Vera, Olga Vikulov. Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study. Diabetes, obesity & metabolism. 2024-04-19. PMID:38637981. |
to assess the impact of insulin glargine (100 u/ml) and lixisenatide (iglarlixi) fixed-ratio combination therapy on the overall management of glycaemia in patients with type 2 diabetes (t2d), previously inadequately controlled with oral antidiabetic drugs ± basal insulin or glucagon-like peptide-1 receptor agonists (glp-1 ras). |
2024-04-19 |
2024-04-21 |
Not clear |
| Giulia Angelini, Sara Russo, Geltrude Mingron. Incretin hormones, obesity and gut microbiota. Peptides. 2024-04-18. PMID:38636809. |
gip (glucose-dependent insulinotropic polypeptide) and glp-1 (glucagon-like peptide-1), which are secreted from the intestine after nutrient intake and stimulate insulin secretion from pancreatic β cells, influence lipid metabolism, gastric empting, appetite and body weight. |
2024-04-18 |
2024-04-21 |
Not clear |
| Ghinwa Barakat, Ghaith Assi, Hussein Khalil, Sami El Khati. A Comprehensive Review on GLP-1 Signaling Pathways in the Management of Diabetes Mellitus - Focus on the Potential Role of GLP-1 Receptors Agonists and Selenium Among Various Organ Systems. Current diabetes reviews. 2024-04-17. PMID:38629376. |
it has been shown that glp-1 efficiently increases insulin production, lowers blood sugar levels in patients with type 2 diabetes mellitus, and decreases appetite, craving, and hunger, therefore amplifying the sensation of fullness and satiety. |
2024-04-17 |
2024-04-19 |
Not clear |
| Anne-Sofie H Jensen, Henriette Ytting, Mikkel P Werge, Elias B Rashu, Liv E Hetland, Mira Thing, Puria Nabilou, Johan Burisch, Kirstine N Bojsen-Møller, Anders E Junker, Lise Hobolth, Christian Mortensen, Flemming Tofteng, Flemming Bendtsen, Søren Møller, Mogens Vyberg, Reza R Serizawa, Lise L Gluud, Nicolai J Wewer Albrechtse. Patients with autoimmune liver disease have glucose disturbances that mechanistically differ from steatotic liver disease. American journal of physiology. Gastrointestinal and liver physiology. 2024-04-16. PMID:38625142. |
we measured the concentrations of glucose, c-peptide, insulin, glucagon, the two incretin hormones glucose insulinotropic peptide (gip) and glucagon-like peptide-1 (glp-1). |
2024-04-16 |
2024-04-18 |
Not clear |
| Lampros G Chrysavgis, Spyridon Kazanas, Konstantina Bafa, Sophia Rozani, Maria-Evangelia Koloutsou, Evangelos Cholongita. Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature. International journal of molecular sciences. vol 25. issue 7. 2024-04-13. PMID:38612640. |
glucagon-like peptide 1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are incretins that regulate postprandial glucose regulation, stimulating insulin secretion from pancreatic β-cells in response to food ingestion. |
2024-04-13 |
2024-04-15 |
human |
| Junping Guo, Xinghua Chen, Cole Wang, Feng Ruan, Yunhe Xiong, Lijun Wang, Osama Abdel-Razek, Qinghe Meng, Rauf Shahbazov, Robert N Cooney, Guirong Wan. LIRAGLUTIDE ALLEVIATES ACUTE LUNG INJURY AND MORTALITY IN PNEUMONIA-INDUCED SEPSIS THROUGH REGULATING SURFACTANT PROTEIN EXPRESSION AND SECRETION. Shock (Augusta, Ga.). vol 61. issue 4. 2024-04-12. PMID:38150354. |
glucagon-like peptide 1 (glp-1) analogs are used to treat type 2 diabetes, and they can regulate insulin secretion, energy homeostasis, inflammation, and immune cell function. |
2024-04-12 |
2024-04-14 |
mouse |
| H B Carslake, G L Pinchbeck, C M Argo, A H A Dugdale, C M McGowa. Investigation of glucagon-like peptide-1 response to six oral carbohydrates in ponies. Veterinary journal (London, England : 1997). 2024-04-11. PMID:38604332. |
glucagon-like peptide-1 (glp-1), the principal incretin in horses, may play a role in the pathophysiology of insulin dysregulation (id). |
2024-04-11 |
2024-04-14 |
Not clear |
| H B Carslake, G L Pinchbeck, C M Argo, A H A Dugdale, C M McGowa. Investigation of glucagon-like peptide-1 response to six oral carbohydrates in ponies. Veterinary journal (London, England : 1997). 2024-04-11. PMID:38604332. |
glucose, insulin and glp-1 concentrations were measured before and following each intervention. |
2024-04-11 |
2024-04-14 |
Not clear |
| Zhenyu Liu, Huixi Kong, Baoyu Zhan. Narrative literature review of antidiabetic drugs' effect on hyperuricemia: elaborate on actual data and mechanisms. Endocrine connections. 2024-04-05. PMID:38579756. |
we find that insulin and dipeptidyl peptidase 4 inhibitor (dpp-4i) except linagliptin could increase the sua, and other drugs including metformin, thiazolidinediones (tzds), glucagon-like peptide-1 receptor agonists (glp-1 ras), linagliptin, sodium-glucose cotransporter 2 inhibitors (sglt2i) and α-glucosidase inhibitors have a reduction effect on sua. |
2024-04-05 |
2024-04-10 |
Not clear |
| Svjatoslavs Kistkins, Othmar Moser, Vitālijs Ankudovičs, Dmitrijs Bliznuks, Timurs Mihailovs, Sergejs Lobanovs, Harald Sourij, Andreas F H Pfeiffer, Valdis Pirag. From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity. Endocrine connections. 2024-04-05. PMID:38579770. |
from classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and glp-1 for the treatment of diabesity. |
2024-04-05 |
2024-04-10 |
Not clear |